Conflicts of interest None declared.
U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease
Version of Record online: 30 JAN 2008
© 2008 The Authors
British Journal of Dermatology
Volume 158, Issue 4, pages 659–678, April 2008
How to Cite
Scarisbrick, J.J., Taylor, P., Holtick, U., Makar, Y., Douglas, K., Berlin, G., Juvonen, E., Marshall, S. and on behalf of the Photopheresis Expert Group (2008), U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. British Journal of Dermatology, 158: 659–678. doi: 10.1111/j.1365-2133.2007.08415.x
In addition to the authors, the Photopheresis Expert Group comprises Kristin Ryggen (Trondheim, Norway), Ian Gosling, Ruti Leci and Sukran Saglam (St John’s Instiute of Dermatology), Emma Das-Gupta, Rebecca Ellis and Lynne Watson (Nottingham City Hospital), Carol Shaw (National Blood Service, Manchester), Eileen Parry (Manchester Hope Hospital), Gordon Cook (Leeds St James’ Hospital), Fiona Clark (University Hospitals Birmingham) and Curly Morris and Mary Drake (Belfast City Hospital).
- Issue online: 30 JAN 2008
- Version of Record online: 30 JAN 2008
- Accepted for publication 25 October 2007
- chronic graft-versus-host disease;
- consensus statement;
- cutaneous T-cell lymphoma;
- extracorporeal photopheresis;
- Sézary syndrome;
- treatment protocol
Extracorporeal photopheresis (ECP) has been used for over 30 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic graft-versus-host disease (cGVHD). The lack of prospective randomized trials has led to different centres having different patient selection criteria, treatment schedules, monitoring protocols and patient assessment criteria. ECP for CTCL and cGVHD is available only at six specialized centres across the U.K. In the recent Improving Outcomes Guidance the National Institute for Health and Clinical Excellence endorsed the use of ECP for CTCL and because of the complexity of treatment supported its use in specialized centres and also suggested the need for expansion of this service. In 2005 consultants and senior nurses from all U.K. sites and from Scandinavia formed a Photopheresis Expert Group. This group’s first aim was to produce a consensus statement on the treatment of CTCL and cGVHD with ECP using evidence-based medicine and best medical practice, in order to standardize ECP eligibility, assessment and treatment strategies across the U.K.